Expression data from Lung cancer

Detection, treatment, and prediction of outcome for lung cancer patients increasingly depend on a molecular understanding of tumor development and sensitivity of lung cancer to therapeutic drugs. The application of genomic technologies, such as microarray, is widely used to monitor global gene expression and has built up invaluable information and knowledge, which is essential to the discovery of new insights into the mechanisms common to cancer cells, resulting in the identification of unique, identifiable signatures and specific characteristics. It is likely that application of microarray may revolutionize many aspects of lung cancer being diagnosed, classified, and treated in the near future. We used microarrays to detail the global gene expression patterns of lung cancer. Keywords: Disease state analysis Adjacent normal-tumor matched lung cancer samples were selected at early and late stages for RNA extraction and hybridization on Affymetrix microarrays. A total of 66 samples were used for microarray analysis, including pairwise samples from 27 patients, who underwent surgery for lung cancer at the Taipei Veterans General Hospital, two tissue mixtures from the Taichung Veterans General Hospital (one was adjacent normal lung mixtures and the other was lung adenocarcinoma mixtures), two commercial human normal lung tissues (Clontech (Catalog No. 636524) and Stratagene (Catalog No. 735020)), one immortalized, nontumorigenic human bronchial epithelial cell line (NL-20 (ATCC® No. CRL-2503)), and 7 lung cancer cell lines (A-549 (ATCC® No. CCL-185), NCI-H1299 (ATCC® No. CRL-5803), NCI-H661 (ATCC® No. HTB-183), CL1-0, CL1-1, CL1-5 and CL1-5-F4.

肺癌患者的检测、治疗与预后预测，愈发依赖对肿瘤发生发展及肺癌对治疗药物敏感性的分子层面认知。基因组技术（如微阵列（microarray））的应用已被广泛用于监测全基因组基因表达谱，积累了极具价值的信息与知识储备，这对于揭示癌细胞共通机制的全新研究见解至关重要，进而助力识别出独特可鉴的分子标记与特异性特征。微阵列技术的应用有望在不久的将来革新肺癌的诊断、分型与治疗诸多环节。本研究借助微阵列技术，细致解析了肺癌的全基因组基因表达谱。
关键词：疾病状态分析
选取早、晚期肺癌的癌旁正常-肿瘤配对样本开展RNA提取，并在Affymetrix微阵列上完成杂交实验。本次微阵列分析共纳入66份样本，具体包括：27例于台北荣民总医院接受肺癌手术患者的配对样本；台中荣民总医院提供的2份组织混合物（分别为癌旁正常肺组织混合物与肺腺癌组织混合物）；2份商业化人类正常肺组织（Clontech，货号636524；Stratagene，货号735020）；1株永生化非致瘤性人类支气管上皮细胞系NL-20（ATCC® 货号CRL-2503）；以及7株肺癌细胞系：A-549（ATCC® 货号CCL-185）、NCI-H1299（ATCC® 货号CRL-5803）、NCI-H661（ATCC® 货号HTB-183）、CL1-0、CL1-1、CL1-5与CL1-5-F4。